Skip to Content

Rivastigmine Teva

Active Substance: rivastigmine
Common Name: rivastigmine
ATC Code: N06DA03
Marketing Authorisation Holder: Teva Pharma B.V.
Active Substance: rivastigmine
Status: Withdrawn
Authorisation Date: 2009-04-17
Therapeutic Area: Dementia Parkinson Disease Alzheimer Disease
Pharmacotherapeutic Group: Anticholinesterases

Therapeutic Indication

Symptomatic treatment of mild to moderately severe Alzheimer's dementia.

Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.

The marketing authorisation for Rivastigmine Teva has been withdrawn at the request of the marketing-authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.